Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039676 · ClinicalTrials.gov registry record
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
A clinical trial of Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- 1,836
- Enrollment target
- 2
- Study locations
NCT00039676 is a study of Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 1,836 participants, above the 172-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (967% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT00039676, a study of Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- 1,836 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: * Individuals may be prone to develop blood or lymph node cancers (leukemia or lymphoma) for a variety of reasons, including genetic predisposition to these cancers, environmental exposures or other medical conditions. * Studies of people and families at high risk of cancer often lead to clues about their cause that may also be important regarding the sporadic occurrence of these cancers in the general population. * Identifying genetic or environmental factors that play a role in the development of these diseases may be important in developing prevention trials, screening programs and treatments. Objectives: * Describe the cancers and other conditions in families with blood or lymph node cancer. * Find and describe genes that may cause blood and lymph node cancer, and understand how they work in families. * Use laboratory methods to try to determine if it is possible to identify who is at highest risk of blood or lymph node cancer. * Test how genes act with other factors to alter the risk of disease, its severity or its manifestations in families. Eligibility: * Individuals of any age with a personal or family history of a blood or lymph node cancer. * Individuals with a personal or family history of medical conditions or environmental exposures that may predispose to blood or lymph node cancer. Design: * Participants complete questionnaires about their personal and family medical history and provide consent for researchers to review their medical records and pathology materials related to their care and those of deceased relatives with blood or lymph node cancer, tumors, or other related illnesses for whom they are the legally authorized representative. * Participants donate a sample of blood or cheek cells, or a lock of hair for genetic studies. * Patients may also be evaluated at the NIH Clinical Center by one or more of the following specialists: cancer doctor or blood specialist, medical geneticist, research nurses or clinical social worker.
Conditions Studied
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center - Bethesda
- NIH National Cancer Institute - Shady Grove - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,836 participants |
| Start Date | 2002-07-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039676
The ClinicalTrials.gov registry entry for NCT00039676 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,836 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 172-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (967% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT00039676 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00039676 about?
NCT00039676 is a clinical study titled "Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer". Background: * Individuals may be prone to develop blood or lymph node cancers (leukemia or lymphoma) for a variety of reasons, including genetic predisposition to these cancers, environmental exposures or other medical conditions. * Studies of people and families at high risk of cancer often lead t...
What is the current status of trial NCT00039676?
This trial is currently active not recruiting. The enrollment target is 1,836 participants. The study started on 2002-07-08.
What conditions does trial NCT00039676 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Hodgkin Disease, NonHodgkin Lymphoma, Mixed Lymphoproliferative Disease.
Who is sponsoring clinical trial NCT00039676?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00039676 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
RECRUITING
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.